This Month in JAAD Case Reports: April 2024: Anifrolumab for subacute cutaneous lupus

Anifrolumab is a first-in-class type I interferon receptor antibody approved by the United States Food and Drug Administration in 2021 for moderate to severe systemic lupus erythematosus. Each of the 3 major anifrolumab clinical trials carried a secondary end point evaluating cutaneous lupus erythematosus (CLE) improvement, though the subtypes of CLE were not reported. At week 52, 46% to 65% of patients on anifrolumab versus 25% to 31% on placebo with a Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) of ≥10 at baseline achieved a ≥50% reduction in CLASI-A.

Source: Journal of the American Academy of Dermatology - January 19, 2024 Category: Dermatology Authors: Brett Sloan Tags: This month in Source Type: research